Matinas BioPharma reports $28.8M cash, focuses LNC on nucleic acids, pauses MAT2203 Phase 3 for BARDA

Matinas BioPharma Holdings, Inc.

Preliminary cash of $28.8M at Dec 31, 2022, down from $49.6M at Dec 31, 2021; runway projected into Q2 2024.
LNC platform achieves intracellular delivery of larger nucleic acids, mRNA stable >10 weeks at 4°C, low cytotoxicity.
MAT2203 Phase 3 for cryptococcal meningitis paused pending BARDA evaluation; FDA meeting planned Q2 2023 for second Phase 3 study in four invasive fungal infections (approx. 100 patients).
BioNTech collaboration: in vivo studies start Q1 2023, data expected Q2 2023; Resilience initial data in Q2/Q3 2023; Genentech extended through 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.